Enhertu
Daiichi Sankyo and Alteogen Collaborate on Subcutaneous Enhertu Development in $300M Licensing Agreement
Daiichi Sankyo, Alteogen, subcutaneous Enhertu, $300M licensing deal, human hyaluronidase, cancer treatment
Enhertu Demonstrates Promising Efficacy in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases
Enhertu, Trastuzumab Deruxtecan, HER2-positive metastatic breast cancer, brain metastases, progression-free survival, objective response rate.
NICE Rejects AstraZeneca’s Enhertu for Breast Cancer Treatment Due to Pricing Concerns
NICE, AstraZeneca, Enhertu, Breast Cancer, Pricing, Rejection
AstraZeneca and Daiichi Sankyo’s Enhertu Denied NICE Recommendation for NHS Use, Prompting Calls for Review Process Reform
Enhertu, NICE, AstraZeneca, Daiichi Sankyo, NHS, breast cancer treatment, cost-effectiveness, pricing dispute, review process reform
AstraZeneca and Daiichi Sankyo’s Enhertu Makes History in HER2-Ultralow Breast Cancer Treatment
Enhertu, AstraZeneca, Daiichi Sankyo, HER2-Ultralow Breast Cancer, ASCO, Metastatic Breast Cancer, Trastuzumab Deruxtecan, Antibody-Drug Conjugate (ADC), Breast Cancer Treatment
AstraZeneca and Daiichi Sankyo’s Enhertu Wins Historic FDA Approval as First Tumor-Agnostic HER2-Directed Therapy
Enhertu, AstraZeneca, Daiichi Sankyo, FDA Approval, Tumor-Agnostic, HER2-Directed Therapy, Metastatic HER2-Positive Solid Tumors, Accelerated Approval, DESTINY-PanTumor02 Study, Objective Response Rate (ORR), Duration of Response (DoR)
NICE Rejects Coverage for AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Enhertu Due to Cost-Effectiveness Concerns
NICE, Enhertu, AstraZeneca, Daiichi Sankyo, Breast cancer, Cost-effectiveness, Coverage rejection, Technology Appraisal, National Health Service (NHS)